/
DCF Valuation
Base-case fair value
$0.90
Intrinsic $1.19 · 25% MOS
Current price: $14.49
Base-case summary
Our base-case DCF for Amicus Therapeutics, Inc. (FOLD) projects 10 years of free cash flow growth at 2.0% for years 1–5 and 1.0% for years 6–10, anchored to a default 8% growth assumption, then applies a 2.5% perpetual growth rate and a 8.0% discount rate. Starting from $30M in trailing free cash flow, this produces an intrinsic value of $1.19 per share. A 25% safety margin gives a fair value of $0.90, suggesting the stock is currently 94% overvalued against the $14.49 market price.
See 3 scenarios side by side
Conservative, Base, and Optimistic fair values, plus the sensitivity matrix and FCF history. Free account.
Model inputs
TTM Free Cash Flow
$30M
Cash & equivalents
$294M
Total debt
$442M
Shares outstanding
308M